Principal Financial Group
NPCE icon

Principal Financial Group’s Neuropace NPCE Stock Holding History

Principal Financial Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,418
Closed -$902K – 2258
2025
Q4 		$902K Buy
58,418
+18,914
+48% +$253K ﹤0.01% 1967
2025
Q3 		$407K Buy
39,504
+21,439
+119% +$202K ﹤0.01% 2086
2025
Q2 		$201K Buy
+18,065
New +$226K ﹤0.01% 2129

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Principal Financial Group's NPCE Position: Q1 2026 in Review

Principal Financial Group sold out of Neuropace (NPCE) in Q1 2026, closing a stake of 58,418 shares — an estimated $902K sold.

Principal Financial Group first reported a position in NPCE in Q2 2025 and held it in 3 quarters. The position peaked at $902K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Principal Financial Group reported no remaining Neuropace position as of Q1 2026 after selling out during the quarter.
  • Principal Financial Group sold 58,418 Neuropace shares in Q1 2026, an estimated $902K.
  • Principal Financial Group first reported a position in Neuropace in Q2 2025 and held it in 3 quarters.
  • Principal Financial Group's Neuropace position peaked at $902K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.